Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 7/20 | 0.57 |
| ▸ | MAOB | P27338 | 7/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | TLR4 | O00206 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FURIN | P09958 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30855377 | 1.00 | NPC1 (0.59) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL5255935 | 0.95 | NPC1 (0.55) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL4748638 | 0.95 | NPC1 (0.55) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL30461144 | 0.95 | NPC1 (0.55) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL30622749 | 0.95 | NPC1 (0.55) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL695627 | 0.92 | NPC1 (0.57) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL5543437 | 0.91 | MAOA (0.66) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL5001878 | 0.87 | NPC1 (0.54) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL9059700 | 0.86 | MAOA (0.70) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL22181586 | 0.86 | MAOA (0.60) | NPC1RAB9ATDP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55098163-A | — | — | None | — | — | JP | disclosed |
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2024-10-31 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4384516-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | Texas Heart Institute (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-117916237-A | Amino aryl integrin agonist compounds | 德克萨斯心脏研究所 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2023018472-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-02-16 | — | — | WO | disclosed |
| US-6825231-B2 | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-30 | — | — | US | disclosed |
| EP-1458707-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053330-A2 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER’S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | disclosed |
| EP-1255724-A1 | SUBSTITUTED NORBORNYLAMINO DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR A DIAGNOSTIC REAGENT AND MEDICAMENTS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-11-13 | — | — | EP | disclosed |
| CN-1379756-A | Substituted nor bornylamino derivatives, method for production thereof, use thereof as medicament or diagnostic reagent medicaments containing said compounds | AVENTIS PHARMA GMBH (DE) | 2002-11-13 | — | — | CN | disclosed |
| US-20010023257-A1 | Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-09-20 | — | — | US | disclosed |
| WO-2001044164-A1 | SUBSTITUTED NORBORNYLAMINO DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR A DIAGNOSTIC REAGENT AND MEDICAMENTS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-21 | — | — | WO | disclosed |
| US-4533668-A | N-ARALKYL AND N-ARALKENYLMORANOLINES | NIPPON SHINYAKU CO. LTD. (JP) | 1985-08-06 | — | — | US | disclosed |
| JP-S5598163-A | CINNAMYLMORANOLINE DERIVATIVE | NIPPON SHINYAKU CO LTD | 1980-07-25 | — | — | JP | disclosed |
| US-3962219-A | DISTYRYL-BENZOBISOXAZOLES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | NPC1 47/4885RAB9A 2120/4885TDP1 499/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | NPC1 47/4885RAB9A 2078/4885TDP1 529/4885 |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | ATM, CHEK2, CHEK1 | NPC1 2161/4885RAB9A 3172/4885TDP1 160/4885 |
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | ITGB3, ITGA2, ITGAV | NPC1 1663/4885RAB9A 949/4885TDP1 4743/4885 |
| US-20010023257-A1 | Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them | ABCB11, SLC10A1, ATP1A2 | NPC1 11/4885RAB9A 2396/4885TDP1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.